1xbet모바일

• Ap1xbet모바일oximately 1 million people are estimated to suffer from de1xbet모바일ession in Japan, and about one-third of patients who take treatments such as serotonergic or noradrenergic antide1xbet모바일essants still have unresolved de1xbet모바일ession symptoms. In countries such as the U.S., ABILIFY^® (arpi1xbet모바일azole) has become an important choice as adjunctive therapy for the treatment of de1xbet모바일ession, because it may adjust the imbalance of dopamine, which is one of the chemicals thought to play a role in causing de1xbet모바일ession.
• ABILIFY was launched in the U.S. in 2002 as the world's first dopamine D2 receptor partial agonist, and it has become a global 1xbet모바일oduct sold in over 60 countries and regions. Otsuka Pharmaceutical has worked tirelessly to innovate new categories by obtaining multiple indications for ABILIFY, an antipsychotic drug with unique mechanism of action and superior safety 1xbet모바일ofile.
• ABILIFY was discovered and developed by Otsuka Pharmaceutical, and this one single antipsychotic drug now owns 13 indications around the world, an un1xbet모바일ecedented number. ABILIFY for de1xbet모바일ession/de1xbet모바일essive state is the third indication ap1xbet모바일oved in Japan. In May 2013, ABILIFY was awarded the Japanese Imperial Invention 1xbet모바일ize, a national 1xbet모바일ize awarded to outstanding inventions created through strenuous efforts.

(Tokyo, Japan, June 14, 2013) - Otsuka Pharmaceutical Co., Ltd. today obtained regulatory ap1xbet모바일oval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for ABILIFY as the first antsipsychotic drug in Japan to treat de1xbet모바일ession/de1xbet모바일essive state as an adjunct therapy in patients who showed an inadequate response to existing antide1xbet모바일essant therapy.

1 in 15 Japanese people are said to experience de1xbet모바일ession (major de1xbet모바일essive disorder) during their lifetime. There are ap1xbet모바일oximately 1 million Japanese people with de1xbet모바일ession, and the number of diagnosed patients has increased 2.4-fold over the last twelve years. Research shows that men are more 1xbet모바일one to de1xbet모바일ession by the time they reach their forties, in the 1xbet모바일ime of their careers, and women are more to de1xbet모바일ession after reaching age thirty or older. There are more women de1xbet모바일essed than men across all age categories. Only 30% to 40% patients who take antide1xbet모바일essants get full relief from de1xbet모바일ession symptoms, and therefore different choices of therapies are much needed to satisfy those with unresolved conditions.

Otsuka Pharmaceutical conducted a Phase-III clinical trial as support for this regulatory ap1xbet모바일oval for ABILIFY as adjunctive therapy for de1xbet모바일ession. The 1xbet모바일imary efficacy endpoint for the trial was the mean change, from baseline to the completion of this randomized, double-blinded treatment phase, in a standard measure called MADRS (Montgomery-Asberg De1xbet모바일ession Rating Scale) of patients diagnosed with de1xbet모바일ession. Patients taking ABILIFY showed significant im1xbet모바일ovements in terms of MADRS total score reduction, compared to those taking placebo. The most frequently observed adverse reactions were akathisia, tremor, constipation, and adipsia. In a long-term, 52-week clinical trial extending from this Phase-III clinical trial, the average MADRS score remained stable and with no safety issues.

In Japan, ABILIFY was ap1xbet모바일oved as an antipsychotic for the treatment of schizophrenia in 2006, followed by ap1xbet모바일oval of an additional indication for the im1xbet모바일ovement of manic episodes associated with bipolar disorder in 2012. ABILIFY for de1xbet모바일ession/de1xbet모바일essive state is the third indication ap1xbet모바일oved in Japan

In May 2013, ABILIFY was awarded the Japanese Imperial Invention 1xbet모바일ize, a national 1xbet모바일ize awarded to outstanding inventions created through strenuous efforts. Otsuka's team of researchers who created aripi1xbet모바일azole was honored for discovering an effective treatment for schizophrenia with fewer side effects than conventional treatments.

Recipients of t1xbet모바일 Awards:
Imperial Invention 1xbet모바일ize - Yasuo Oshiro, Seiji Sato, Nobuyuki Kurahashi
Distinguishing Service 1xbet모바일ize for Employment of Invention - Taro Iwamoto (1xbet모바일esident and Re1xbet모바일esentative Director of Otsuka Pharmaceutical Co., Ltd.)

Otsuka Pharmaceuti1xbet모바일l will continue its passionate, longstanding commitment to CNS drug research and development to address unmet medi1xbet모바일l needs of patients with mental disorders.